Pathogenic CCR6+ dendritic cells in the skin lesions of discoid lupus patients: A role for damage-associated molecular patterns

European Journal of Dermatology

Volumn 23, Issue 2, 2013, Pages 169-182

  Méndez Reguera, Aniela ^a,d   Pérez Montesinos, Gibrán ^a,b   Ntarahernández, Marcela Alcá ^a   Mart́inez Estrada, Virginia ^b   Cazarinbarrientos, Jorge Rafael ^c   Rojas Espinosa, Oscar ^d   Jurado Santacruz, Fermín ^b   Huerta Yepez, Sara ^e   Bonifaz Alfonzo, Laura ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b CENTRO DERMATOLÓGICO DR LADISLAO DE LA PASCUA   (Mexico)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

^d INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^e HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

Damage associated molecular patterns; Dendritic cells; Dermal dendritic cells; Discoid lupus erythematosus; Inflammatory dendritic cells

Indexed keywords

CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD40 ANTIGEN; CD56 ANTIGEN; CD83 ANTIGEN; CHEMOKINE RECEPTOR CCR6; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGRAMMED DEATH 1 LIGAND 1; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DENDRITIC CELL; DERMATITIS; DERMIS; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NICK END LABELING; PHENOTYPIC VARIATION; PUNCH BIOPSY; SKIN BIOPSY; SKIN DISEASE; STEM CELL MOBILIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE MICROARRAY;

DAMAGE ASSOCIATED MOLECULAR PATTERNS; DENDRITIC CELLS; DERMAL DENDRITIC CELLS; DISCOID LUPUS ERYTHEMATOSUS; INFLAMMATORY DENDRITIC CELLS;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD11C; ANTIGENS, CD274; ANTIGENS, CD40; APOPTOSIS; CELL COUNT; CELL MOVEMENT; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LUPUS ERYTHEMATOSUS, DISCOID; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, CCR6; SKIN; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84877764602     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2013.1970     Document Type: Article

References (46)

1. Werth VP. Cutaneous lupus: insights into pathogenesis and disease classification. Bull NYU Hosp Jt Dis 2007; 65: 200-204.
2. Stein LF, Saed GM, Fivenson DP. T-cell cytokine network in cutaneous lupus erythematosus. J Am Acad Dermatol 1997; 36: 191-196.
3. Toro JR, Finlay D, Dou X, et al. Detection of type 1 cytokines in discoid lupus erythematosus. Arch Dermatol 2000; 136: 1497-1501.
4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
5. Steinman RM, Hawiger D, Liu K, et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 2003; 987: 15-25.
6. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711.
7. Kohrgruber N, Halanek N, Groger M, et al. Survival, maturation, and function of CD11c- and CD11c+ peripheral blood dendritic cells are differentially regulated by cytokines. J Immunol 1999; 163: 3250-3259.
8. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284: 1835-1837.
9. Schakel K, Mayer E, Federle C, et al. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol 1998; 28: 4084-4093.
10. Schakel K, Poppe C, Mayer E, et al. M-DC8+ leukocytes-a novel human dendritic cell population. Pathobiology 1999; 67: 287-290.
11. Schakel K, Kannagi R, Kniep B, et al. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 2002; 17: 289-301.
12. Hansel A, Gunther C, Ingwersen J, et al. Human slan (6-sulfo Lac- NAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J Allergy Clin Immunol 2011; 127: 787-94 e1-94e9.
13. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 2008; 8: 935-47.
14. Nestle FO, Zheng XG, Thompson CB, et al. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J Immunol 1993; 151: 6535-6545.
15. Zaba LC, Fuentes-Duculan J, Steinman RM, et al. Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J Clin Invest 2007; 117: 2517-2525.
16. Wollenberg A, Wagner M, Gunther S, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002; 119: 1096-1102.
17. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-143.
18. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204: 3183-3194.
19. Zaba LC, Krueger JG, Lowes MA. Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol 2009; 129: 302-308.
20. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25: 383-392.
21. Ronnblom L, Alm GV. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001; 194: F59-F63.
22. Crispin JC, Alcocer-Varela J. The role myeloid dendritic cells play in the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2007; 6: 450-456.
23. Decker P, Kotter I, Klein R, et al. Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2006; 45: 1087-1095.
24. Gerl V, Lischka A, Panne D, et al. Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function. Ann Rheum Dis 2010; 69: 1370-1377.
25. Blomberg S, Eloranta ML, Cederblad B, et al. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 2001; 10: 484-490.
26. Farkas L, Beiske K, Lund-Johansen F, et al. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001; 159: 237-243.
27. Hedrick MN, Lonsdorf AS, Hwang ST, et al. CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets 2010; 14: 911-922.
28. Liston A, Kohler RE, Townley S, et al. Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response. J Immunol 2009; 182: 3121-3130.
29. Hedrick MN, Lonsdorf AS, Shirakawa AK, et al. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest 2009; 119: 2317-2329.
30. Elhofy A, Depaolo RW, Lira SA, et al. Mice deficient for CCR6 fail to control chronic experimental autoimmune encephalomyelitis. J Neuroimmunol 2009; 213: 91-99.
31. Wenzel J, Zahn S, Tuting T. Pathogenesis of cutaneous lupus erythematosus: common and different features in distinct subsets. Lupus 2010; 19: 1020-1028.
32. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol 2007; 119: 1210-1217.
33. Johnson-Huang LM, McNutt NS, Krueger JG, et al. Cytokineproducing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol 2009; 29: 247-256.
34. Wenzel J, Uerlich M, Worrenkamper E, et al. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol 2005; 153: 1011-1015.
35. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009; 129: 79-88.
36. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005; 102: 19057-19062.
37. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 198: 63-69.
38. Salama AD, Chitnis T, Imitola J, et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003; 198: 71-78.
39. Hewitt RE, Pele LC, Tremelling M, et al. Immuno-inhibitory PDL1 can be induced by a peptidoglycan/NOD2 mediated pathway in primary monocytic cells and is deficient in Crohn's patients with homozygous NOD2 mutations. Clin Immunol 2012; 143: 162-169.
40. Chu CC, Ali N, Karagiannis P, et al. Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med 2012; 209: 935-945.
41. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015-3029.
42. Latchman YE, Liang SC, Wu Y, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A 2004; 101: 10691-10696.
43. Gunther C, Starke J, Zimmermann N, et al. Human 6-sulfo LacNAc (slan) dendritic cells are a major population of dermal dendritic cells in steady state and inflammation. Clin Exp Dermatol 2011; 37: 169-176.
44. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-569.
45. Kruse K, Janko C, Urbonaviciute V, et al. Inefficient clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis 2012; 15: 1098-1113.
46. Kuhn A, Meuth AM, Bein D, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 2010; 163: 83-92.